CAHC’s Joel White spoke with BioSpace about the Inflation Reduction Act’s small molecule penalty and its impact on the research and development of new treatments.
“There is a valid concern that the price negotiation period is not enough time for small molecule manufacturers to recoup R&D costs,” Joel White, president of the Council for Affordable Health Coverage, wrote in an email to BioSpace. “We are already seeing biotech companies shifting investment away from small-molecule drugs.”